No conflicts of interest or relationships to disclose.
Disclaimer

Funding for this presentation was made possible by U1OHA29296 from the Human Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.
Data in this presentation offer a limited perspective of how systemic, social, and economic factors impact health. We recognize that racism, not race, creates and perpetuates health disparities.

To Learn More:
https://www.cdc.gov/minorityhealth/racism-disparities
LEARNING OBJECTIVES

1. To identify the role of buprenorphine as a medication for opioid use disorder (MOUD).
2. To describe approaches to counseling patients on MOUD options.
3. To outline practical considerations for buprenorphine initiation for OUD.
Addressing substance use disorders in people with HIV is important for several reasons.

Substance use can:
- Drive transmission of HIV infection (e.g. injection drug use)
- Increase high-risk sexual behaviors
- Reduce HIV treatment adherence
- Worsen neurologic and other complications of HIV infection
- Increase viral load, further disease progression, and increase mortality in people with HIV even if on ART regimen (Dash 2015)

Treating SUD can:
- Reduce risk of HIV acquisition and transmission
- Improve HIV and other medical treatment adherence
Fentanyl pressed pills ("blues")
LEARNING OBJECTIVES

1. To identify the role of buprenorphine as a medication for opioid use disorder (MOUD).
2. To describe approaches to counseling patients on MOUD options.
3. To outline practical considerations for buprenorphine initiation for OUD.
FDA APPROVED MEDICATIONS FOR OUD (MOUD)

From Jonathan Buchholz, MD
BUPRENORPHINE

- Partial agonist at mu opioid receptor (MOR)
- Ceiling effect on respiratory depression (lower risk of overdose)
- High affinity for MOR (displaces other opioids)
- Poor oral bioavailability; given sublingually or subcutaneously for OUD (transdermal or buccal for pain)
- Sublingual:
  - Peak level 3-6 hours
  - 24-48 hour duration
  - Half life >24 hours
  - Typical maintenance dose: 16-24 mg daily (typical maximum 32 mg daily)
## BUPRENORPHINE MOUD FORMULATIONS

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dosing</th>
<th>FDA-Approved Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet (Sublingual)</td>
<td>Daily</td>
<td>Generic, buprenorphine-naloxone SL (Suboxone, Zubsolv), buprenorphine (Subutex)</td>
</tr>
<tr>
<td>Film (Sublingual)</td>
<td>Daily</td>
<td>Generic, buprenorphine-naloxone (Suboxone)</td>
</tr>
<tr>
<td>Extended-Release Injection</td>
<td>Monthly or Weekly</td>
<td>Buprenorphine monthly (Sublocade) Buprenorphine weekly or monthly (Brixadi)</td>
</tr>
<tr>
<td>(Subcutaneous)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
A NOTE ON BUPRENORPHINE PRESCRIBING…

• Buprenorphine for OUD can now be prescribed by anyone with DEA registration including Schedule III authority as of 1/12/2023. **No X-waiver needed!**

• After 6/27/2023, for new or renewing DEA registrations, a **one-time requirement of 8 hours of training on substance use disorders (SUDs)** is now required

• If you previously got your X-waiver, this counts!

SAMHSA
LEARNING OBJECTIVES

1. To identify the role of buprenorphine as a medication for opioid use disorder (MOUD).

2. To describe approaches to counseling patients on MOUD options.

3. To outline practical considerations for buprenorphine initiation for OUD.
COUNSELING ON OUD TREATMENT

• Discuss main key components of treatment
  – Medications for opioid use disorder (MOUD)
  – Psychosocial interventions (e.g. counseling, mutual support groups)
• First-line treatment for OUD is medications, with adjunctive psychosocial interventions
• Shared decision-making is key!
• Decreased mortality is associated with opioid agonist treatment (buprenorphine or methadone)
POSSIBLE REASONS TO CHOOSE BUPRENOHRPHINE

• Desire to avoid treatment in OTP setting
  – Structured setting
  – Location
  – Need for observed dosing and dispensing at OTP
• Desire to receive care in integrated care setting (e.g. from PCP/OBOT program)
• Methadone side effects or drug-drug interactions
• Dosing schedule and route of administration
  – e.g. Buprenorphine XR injectable form
• Preparation for transition to opioid antagonist treatment (naltrexone)
• Patient-driven (rather than provider-driven) transitions to buprenorphine are associated with higher rate of success! (Bhatraju 2022)
LIMITATIONS OF BUPRENORPHINE

• Difficulty with tolerating opioid withdrawal
• Risk of return to use when opioid agonist dose is tapered
  – For example, in methadone to buprenorphine transitions
• Precipitated withdrawal if buprenorphine given too soon after stopping opioid agonist (especially with fentanyl)
• Inability to quickly achieve therapeutic effect with buprenorphine
LEARNING OBJECTIVES

1. To identify the types of medications for opioid use disorder (OUD), with focus on buprenorphine.
2. To describe approaches to counseling patients on MOUD options.
3. To outline practical considerations for buprenorphine initiation for OUD.
BUPRENORPHINE INITIATION PROTOCOLS

- Standard initiation
- High-dose initiation
- Low-dose initiation
- Practical considerations
STANDARD BUPRENORPHINE INITIATION

• Stop opioids and wait until patient is in opioid withdrawal (COWS>10 typically), usually after:
  – Short-acting opioids (heroin, hydrocodone, oxycodone): 12-16 hr
  – Intermediate-acting opioids (e.g. oxycodone ER): 17-24 hr
  – Long-acting opioids (e.g. methadone, fentanyl): 36+ hours

• Buprenorphine-naloxone started, uptitrated until withdrawal resolves (usually 1-3 days)

• Typically no more than 8-16 mg bup total on day 1

• Pro: less complex protocol

• Cons:
  – Risk for return to use after stopping opioids
  – May take days to achieve therapeutic buprenorphine level
HIGH-DOSE INITIATION
Like conventional initiation, but higher buprenorphine dose on day 1 (16-32 mg)

Wait at least... 12-24 hours since last heroin or fentanyl use

Take 2 tabs or films all at once
Wait 30-60 minutes
Take 1 additional tab or film if needed

16 mg
8 mg

Start taking prescribed withdrawal medications 1-2 hours before first dose of buprenorphine-naloxone

Moderate withdrawal means you have at least 3 of the following...
- Restless
- Yawning
- Runny nose
- Big pupils
- Watery eyes
- No appetite
- Stomach cramps
- Body aches
- Shaking/twitching
- Sweats
- Chills
- Gooselike
- Nausea or vomiting
- Diarrhea

On day 2 start taking 1 tab or film (8 mg) in the morning, afternoon, and evening
HIGH-DOSE INITIATION

• Like conventional initiation, but higher buprenorphine dose on day 1 (16-32 mg)

• Advantages
  – Less complex protocol than low- or standard-dose start
  – Could be more effective in achieving therapeutic dose while minimizing withdrawal period

• Limited evidence in literature (for now)
  – Retrospective studies from ER setting
  – Very few cases of precipitated withdrawal, even with fentanyl use (Snyder 2023, Herring 2021)
LOW-DOSE BUPRENORPHINE INITIATION

• Start buprenorphine at low doses while continuing full agonist (i.e. methadone)
• Intention is to minimize precipitated withdrawal
• Pros:
  – May be more acceptable if negative prior experiences with standard buprenorphine initiation
  – Minimizes withdrawal symptoms
• Cons:
  – More complex instructions
  – Limited evidence in outpatient setting

Hämmig 2016, Bhatraju 2022, Button 2022
### Outpatient Low-Dose 1-Week Initiation Example

<table>
<thead>
<tr>
<th>Day</th>
<th>Actual Dose/Day</th>
<th>Fraction of bup-nal Film (or SL tablets)</th>
<th>Full Opioid Agonist Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>0.5 mg daily</td>
<td>( \frac{1}{4} ) (2/0.5 mg) film once daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 2</td>
<td>0.5 mg BID</td>
<td>( \frac{1}{4} ) (2/0.5 mg) film twice daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 3</td>
<td>1 mg BID</td>
<td>( \frac{1}{2} ) (2/0.5 mg) film twice daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 4</td>
<td>2 mg BID</td>
<td>1 (2/0.5 mg) film twice daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 5</td>
<td>2 mg TID</td>
<td>1 (2/0.5 mg) film three times daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 6</td>
<td>4 mg BID</td>
<td>2 (2/0.5 mg) films twice daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 7</td>
<td>4 mg TID</td>
<td>2 (2/0.5 mg) films three times daily</td>
<td>STOP opioid</td>
</tr>
<tr>
<td>Day 8+</td>
<td>8 mg BID (can titrate up to 32 mg total daily dose)</td>
<td>1 (8/2 mg) film twice daily (can titrate up to 4 films daily)</td>
<td></td>
</tr>
</tbody>
</table>
## OUTPATIENT LOW-DOSE 2-WEEK INITIATION EXAMPLE
(PATIENT TRANSITIONING FROM METHADONE TO BUP)

<table>
<thead>
<tr>
<th>Day</th>
<th>Actual Dose/Day</th>
<th>Film or SL tablets</th>
<th>Methadone Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Buprenorphine/Naloxone Film 2mg/0.5mg</td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>0.5mg</td>
<td>¼ film once daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td></td>
<td>See ETS Medical Provider on Day 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 2</td>
<td>0.5mg once daily</td>
<td>¼ film once daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 3</td>
<td>1mg once daily</td>
<td>½ film once daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 4</td>
<td>1mg once daily</td>
<td>½ film once daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Begin Buprenorphine/Naloxone Tablets for remainder of transition</strong></td>
</tr>
<tr>
<td>Day 5</td>
<td>2mg once daily</td>
<td>1 x 2mg/0.5mg daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 6</td>
<td>2mg once daily</td>
<td>1 x 2mg/0.5mg daily</td>
<td>Continue current dose</td>
</tr>
<tr>
<td>Day 7</td>
<td>4mg once daily</td>
<td>2 x 2mg/0.5mg daily</td>
<td>Meet with your ETS medical provider to discuss when to reduce or discontinue methadone dose.</td>
</tr>
<tr>
<td></td>
<td>See ETS Medical Provider on Day 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 8</td>
<td>4mg once daily</td>
<td>2 x 2mg/0.5mg daily</td>
<td></td>
</tr>
<tr>
<td>Day 9</td>
<td>6mg once daily</td>
<td>3 x 2mg/0.5mg daily</td>
<td></td>
</tr>
<tr>
<td>Day 10</td>
<td>6mg once daily</td>
<td>3 x 2mg/0.5mg daily</td>
<td></td>
</tr>
<tr>
<td>Day 11</td>
<td>8mg once daily</td>
<td>1 x 8mg/2mg daily</td>
<td></td>
</tr>
<tr>
<td>Day 12</td>
<td>8mg once daily</td>
<td>1 x 8mg/2mg daily</td>
<td></td>
</tr>
<tr>
<td>Day 13</td>
<td>12mg once daily</td>
<td>2 x 2mg/0.5mg along with 1 x 8mg/2mg daily</td>
<td></td>
</tr>
<tr>
<td>Day 14</td>
<td>16mg once daily</td>
<td>2 x 8mg/2mg daily</td>
<td>Return to ETS</td>
</tr>
<tr>
<td></td>
<td>See ETS Medical Provider on Day 14</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Evergreen Treatment Services
BUPRENORPHINE FILMS AND TABLETS

$\frac{1}{4}$th of a 2/0.5 mg bup-nal film or tab = 0.5 mg buprenorphine

Can cut the film, or split the tablet, into fourths
COMPARISONS OF PROTOCOLS

• Most studies are observational case series with heterogeneous populations, methods, and reported outcomes
• Low-dose initiation has more evidence for efficacy
• Most data of low-dose initiation is from inpatient setting; limited generalizability to outpatient setting
• Limited data on high-dose transition from methadone to buprenorphine, but anecdotally some potential benefits to this strategy
CONVENTIONAL VS LOW-DOSE BUP INITIATION: COLD WATER ANALOGY
OBOT-BASED BUPRENORPHINE INITIATION: PRACTICAL APPROACH

- Prescribe buprenorphine-naloxone and PRN comfort medications with instructions on home initiation
- Schedule provider visits starting on day 1 of initiation protocol, at least weekly and PRN
- Follow-up via telephone as needed (with RN or other clinic staff)
- If transitioning from methadone to buprenorphine, should collaborate with OTP provider (have ROI signed to allow for communication with OTP)
- If buprenorphine extended-release injectable formulations are available, these have great potential for better adherence to MOUD treatment!
## ADJUNCTIVE MEDICATIONS FOR OPIOID WITHDRAWAL

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Medication</th>
<th>Typical Dose Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety, restlessness, insomnia</td>
<td>Clonidine</td>
<td>0.1-0.2 mg q2H PRN, NTE 1.2 mg daily (avoid if hypotensive), taper by 0.1-0.2 daily</td>
</tr>
<tr>
<td></td>
<td>Gabapentin</td>
<td>300 mg TID PRN</td>
</tr>
<tr>
<td></td>
<td>Hydroxyzine</td>
<td>25-50 mg q6H PRN</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>Methocarbamol</td>
<td>500 mg TID PRN</td>
</tr>
<tr>
<td>Muscle aches, joint pain, headache</td>
<td>Ibuprofen</td>
<td>400-800 q6H PRN</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen</td>
<td>500-1000 mg q6H PRN</td>
</tr>
<tr>
<td>Nausea, vomiting</td>
<td>Ondansetron</td>
<td>4-8 mg q8H PRN</td>
</tr>
<tr>
<td>Abdominal cramping</td>
<td>Dicyclomine</td>
<td>20 mg 4x daily PRN</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Loperamide</td>
<td>2 mg 4x daily PRN</td>
</tr>
</tbody>
</table>

Srivastava 2020
OTHER PRACTICAL CONSIDERATIONS

• Advise patient to consider reducing work, other obligations as able during initiation (likely 1-2 weeks)
• Ensure clinical support (e.g. access to clinic RN via telephone) available for patient PRN during initiation
BUPRENORPHINE INITIATION: SUMMARY

• The decision on MOUD depends on various factors
  – Patient preferences
  – Risk-benefit discussion
  – Adherence considerations
  – Access
• Risks of buprenorphine initiation include risk of return to use or precipitated withdrawal during transition period
• Low-dose buprenorphine initiation has evidence for efficacy; most evidence comes from hospital setting
CASE EXAMPLE 1: OBOT PATIENT

38M with history of OUD, ventral hernia, severe vision impairment, unhoused, presenting to low-barrier OBOT clinic for restart of buprenorphine.

Last seen in OBOT clinic in 2021, prior history of heroin use and started on buprenorphine-naloxone, previously stable on 16 mg daily. Since then, moved to Olympia, began use of fentanyl blues about 1.5 years ago (and stopped heroin). Now taking 15-20 blues daily, occasional fentanyl powder. Has returned to Seattle, staying in tent. Wants to stop fentanyl use. Doesn’t have money to continue buying fentanyl.

Tried to quit fentanyl and start buprenorphine-naloxone (purchased from street) but unsuccessful in the last few weeks. Says that prior successful approach to bup initiation (taking 1-2 Suboxone strips [8-16 mg bup] BID about 24 hours after last use of heroin) hasn't been successful with fentanyl, and sent him into precipitated withdrawal, even when waiting 2 days from last use of fentanyl.

Asks for your help with restarting buprenorphine-naloxone.

- How can you counsel this patient on approaches to starting buprenorphine? What more information might you need?
- What are some pros and cons to traditional, low-, and high-dose initiation approaches?
# CASE EXAMPLE 1: OBOT PATIENT

<table>
<thead>
<tr>
<th>Buprenorphine Initiation Approach</th>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
</table>
| Traditional                       | Simpler instructions  
Can stop using opioids right away | Already tried it, didn’t work due to precipitated withdrawal |
| Low-Dose                          | Minimizes withdrawal risk | Requires continued fentanyl use ($$ is a concern)  
Complex titration instructions, takes a week or more  
Vision impairment |
| High-Dose                         | Simpler instructions  
Fastest method to get onto bup  
Can stop using opioids right away | Risk of precipitated withdrawal  
Patient concerned about GI side effects (with history of ventral hernia)  
Least evidence/experience |

- In the end, patient opted for low-dose buprenorphine-naloxone initiation.
- Buprenorphine-naloxone prescribed, with comfort medications to use PRN (clonidine, gabapentin, ondansetron)
- Naloxone kit given to patient
- Unfortunately did not make it to follow up appointment, outcome not determined
CASE EXAMPLE 2: HOSPITALIZED PATIENT

• 65M history of OUD, gastric adenocarcinoma s/p resection complicated by severe anastamosis stricture, presenting with recurrent stricture resulting in acute on chronic abdominal pain and malnutrition.
• Smoking 10 fentanyl "blues" daily previously.
• Methadone started at 30 mg daily, increased to 35 mg daily
• However complicated by intermittently prolonged QTc >500
• Risk/benefit discussion with patient:
  – Patient willing to transition to buprenorphine
  – Motivated by desire to travel, felt monthly visits to clinic more feasible than frequent OTP clinic visits
  – Risks of precipitated withdrawal discussed
<table>
<thead>
<tr>
<th>Day</th>
<th>Buprenorphine</th>
<th>Methadone</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td>35 mg daily</td>
<td>No withdrawal symptoms</td>
</tr>
<tr>
<td>1</td>
<td>Buprenorphine 450 mcg buccal once</td>
<td>35 mg daily</td>
<td>“Irritability”</td>
</tr>
<tr>
<td>2</td>
<td>Buprenorphine 450 mcg buccal BID</td>
<td>35 mg daily</td>
<td>No change in symptoms</td>
</tr>
<tr>
<td>3</td>
<td>Buprenorphine 900 mcg buccal BID</td>
<td>35 mg daily</td>
<td>No change in symptoms</td>
</tr>
<tr>
<td>4</td>
<td>Buprenorphine-naloxone 2-0.5 mg SL BID</td>
<td>35 mg daily</td>
<td>No change in symptoms</td>
</tr>
<tr>
<td>5</td>
<td>Buprenorphine-naloxone 4-1 mg SL BID</td>
<td>35 mg daily</td>
<td>Restlessness, rhinorrhea</td>
</tr>
<tr>
<td>6</td>
<td>Buprenorphine-naloxone 8-2 mg SL BID</td>
<td>None</td>
<td>Irritability, anxiety, restlessness, rhinorrhea</td>
</tr>
<tr>
<td>7</td>
<td>Buprenorphine-naloxone 8-2 mg SL BID</td>
<td>None</td>
<td>Nausea, diarrhea, but otherwise better</td>
</tr>
</tbody>
</table>

Patient ultimately transitioned to XR buprenorphine 300 mg SC injection by day 10
Discharged with OBOT clinic follow-up for buprenorphine monthly injections
Thank you!

Amy Liu
amy.liu@case.edu
ACKNOWLEDGEMENTS

- Jocelyn James, MD
- Joseph Merrill, MD, MPH
- Jamie Darnton, MD
- Addy Adwell, RN-BC, BSN
- UW Addiction Medicine Fellowship
REFERENCES


REFERENCES


Acknowledgment

This Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $3,333,289 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.